Ventria Bioscience acquires Meristem Therapeutics' recombinant lactoferrin IP
Ventria Bioscience is acquiring exclusive ownership rights to intellectual property relating to Meristem Therapeutics' recombinant human lactoferrin.
Ventria Bioscience is to acquire intellectual property relating to recombinant lactoferrin developed by French biotechnology company Meristem Therapeutics.
Under the terms of the agreement, Ventria Bioscience will obtain exclusive royalty-free ownership rights for specific patents in the US, France and Canada in exchange for a one-off payment.
The agreement includes patents relating to recombinant human lactoferrin, which is the active ingredient in Ventria Bioscience's lead drug candidate VEN100.
VEN100 is currently being developed as a preventive treatment for antibiotic-associated diarrhoea in high-risk adults.
Scott Deeter, president and chief executive officer of Ventria Bioscience, said: "The patents acquired today cover important components of our product pipeline.
"The decision to purchase this intellectual property is significant because it removes the encumbrance of ongoing royalty and milestone payments, thereby enhancing the future economics of our products that use recombinant human lactoferrin."
Ventria Bioscience has solved the problem of producing commercial-scale yields of recombinant human lactoferrin using its proprietary ExpressTec technology platform.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...